Payment overview · 2025
General Payments
59 reported records · 9 companies
Healthcare provider profile · identity verified
Allopathic & Osteopathic Physicians|Orthopaedic Surgery|Foot and Ankle Surgery · PEORIA, IL · NPI 1245721612
Verified facts
CMS Open Payments records show Vincent Gianni Vacketta, DPM received $64,565.70 in general payments during 2025 across 59 reported records.
EXACTECH, INC. accounted for 51.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Payment overview · 2025
59 reported records · 9 companies
Separate record types
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| EXACTECH, INC. | Unresolved — no canonical attribution shown | $32,991.60 | 51.1% | 16 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $14,323.64 | 22.2% | 21 | 2025 |
| Medline Industries LP | Unresolved — no canonical attribution shown | $12,950.34 | 20.1% | 11 | 2025 |
| Flower Orthopedics Coporation | Unresolved — no canonical attribution shown | $3,237.38 | 5.0% | 5 | 2025 |
| Linvatec Corporation | Unresolved — no canonical attribution shown | $800.00 | 1.2% | 2 | 2025 |
| MedShape, Inc. | Unresolved — no canonical attribution shown | $136.23 | 0.2% | 1 | 2025 |
| Arteriocyte Medical Systems, Inc. | Unresolved — no canonical attribution shown | $79.26 | 0.1% | 1 | 2025 |
| TREACE MEDICAL CONCEPTS, INC. | Unresolved — no canonical attribution shown | $29.54 | 0.1% | 1 | 2025 |
| Bioventus LLC | Unresolved — no canonical attribution shown | $17.71 | 0.0% | 1 | 2025 |
What were the payments for?
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $55,639.00 | 15 |
| Travel and Lodging | $5,794.62 | 15 |
| Food and Beverage | $3,132.08 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VANTAGE Normalized: vantage |
Device | EXACTECH, INC. | $30,259.77 | 10 | 2025 |
Source payment records
|
|||||
| Medline Industries, Inc. Normalized: medline industries inc |
Device | Medline Industries LP | $12,042.00 | 3 | 2025 |
Source payment records
|
|||||
| MEDLINE UNITE Normalized: medline unite |
Device | Medline Industries LP | $7,642.00 | 2 | 2025 |
Source payment records
|
|||||
| Medline Normalized: medline |
Device | Medline Industries LP | $7,642.00 | 2 | 2025 |
Source payment records
|
|||||
| PENDING Normalized: pending |
Device | Medline Industries LP | $7,642.00 | 2 | 2025 |
Source payment records
|
|||||
| FLEXBAND Normalized: flexband |
Device | Stryker Corporation | $4,462.16 | 2 | 2025 |
Source payment records
|
|||||
| MILD DEVICE KIT Normalized: mild device kit |
Device | Stryker Corporation | $4,400.00 | 3 | 2025 |
Source payment records
|
|||||
| EPIC FOOT PLATE SYSTEM Normalized: epic foot plate system |
Device | EXACTECH, INC. | $2,731.83 | 6 | 2025 |
Source payment records
|
|||||
| CITREFIX Normalized: citrefix |
Device | Stryker Corporation | $1,602.31 | 4 | 2025 |
Source payment records
|
|||||
| EXACTECHGPS Normalized: exactechgps |
Device | EXACTECH, INC. | $1,364.40 | 3 | 2025 |
Source payment records
|
|||||
| BIOBRACE 23MM Normalized: biobrace 23mm |
Device | Linvatec Corporation | $800.00 | 2 | 2025 |
Source payment records
|
|||||
| 7 X 23MM CITRELOCK IMPLANT Normalized: 7 x 23mm citrelock implant |
Device | Stryker Corporation | $566.60 | 4 | 2025 |
Source payment records
|
|||||
| PRIME SERIES Normalized: prime series |
Device | Stryker Corporation | $200.00 | 1 | 2025 |
Source payment records
|
|||||
| 1788 Normalized: 1788 |
Medical Supply | Stryker Corporation | $145.46 | 1 | 2025 |
Source payment records
|
|||||
| DynaNail Helix, Washer, 15 mm Normalized: dynanail helix washer 15 mm |
Device | MedShape, Inc. | $136.23 | 1 | 2025 |
Source payment records
|
|||||
| ALPHAVENT Normalized: alphavent |
Device | Stryker Corporation | $118.71 | 2 | 2025 |
Source payment records
|
|||||
| Magellan Normalized: magellan |
Device | Arteriocyte Medical Systems, Inc. | $79.26 | 1 | 2025 |
Source payment records
|
|||||
| AUGMENT INJECTABLE Normalized: augment injectable |
Device | Stryker Corporation | $19.34 | 2 | 2025 |
Source payment records
|
|||||
| EXOGEN ULTRASOUND BONE HEALING SYSTEM Normalized: exogen ultrasound bone healing system |
Device | Bioventus LLC | $17.71 | 1 | 2025 |
Source payment records
|
|||||
| PROSTEP Normalized: prostep |
Device | Stryker Corporation | $9.06 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 78 | 54 |
| Cephalexin | Cephalexin | 46 | 43 |
| Tramadol Hcl | Tramadol Hcl | 20 | 14 |
| Clindamycin Hcl | Clindamycin Hcl | 16 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
Timeline
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $64,565.70 · 59 records | EXACTECH, INC. | 1788, 7 X 23MM CITRELOCK IMPLANT, ALPHAVENT, AUGMENT INJECTABLE, BIOBRACE 23MM, CITREFIX, DynaNail Helix, Washer, 15 mm, EPIC FOOT PLATE SYSTEM, EXACTECHGPS, EXOGEN ULTRASOUND BONE HEALING SYSTEM, FLEXBAND, MEDLINE UNITE, MILD DEVICE KIT, Magellan, Medline, Medline Industries, Inc., PENDING, PRIME SERIES, PROSTEP, VANTAGE | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error